[HTML][HTML] Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …
[HTML][HTML] Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
[HTML][HTML] Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1),
glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have …
glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have …
Incretin hormones: Their role in health and disease
Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed
to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) …
to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) …
Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial …
like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial …
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
potentiate glucose-induced insulin secretion and are therefore thought to be responsible for …
potentiate glucose-induced insulin secretion and are therefore thought to be responsible for …
GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women
EW Iepsen, JR Lundgren, B Hartmann… - The Journal of …, 2015 - academic.oup.com
Context: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone
turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight …
turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight …
Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment
SP Schiellerup, K Skov-Jeppesen… - Frontiers in …, 2019 - frontiersin.org
Bone homeostasis displays a circadian rhythm with increased resorption during the night
time as compared to day time, a difference that seems—at least partly—to be caused by food …
time as compared to day time, a difference that seems—at least partly—to be caused by food …
The associations of gut microbiota, endocrine system and bone metabolism
Gut microbiota is of great importance in human health, and its roles in the maintenance of
skeletal homeostasis have long been recognized as the “gut-bone axis.” Recent evidence …
skeletal homeostasis have long been recognized as the “gut-bone axis.” Recent evidence …